A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease

Trial Profile

A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs GSK 2269557 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Pharmacogenomic
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Mar 2017 Last checked against European Clinical Trials Database record.
    • 08 Mar 2017 Planned End Date changed from 1 Jun 2018 to 1 Apr 2018.
    • 08 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top